Robert Fowler to Lopinavir
This is a "connection" page, showing publications Robert Fowler has written about Lopinavir.
Connection Strength
0.308
-
Post-exposure prophylaxis against SARS-CoV-2 in close contacts of confirmed COVID-19 cases (CORIPREV): study protocol for a cluster-randomized trial. Trials. 2021 Mar 22; 22(1):224.
Score: 0.078
-
Interferon Beta-1b and Lopinavir-Ritonavir for Middle East Respiratory Syndrome. N Engl J Med. 2020 10 22; 383(17):1645-1656.
Score: 0.076
-
Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-ß1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial. Trials. 2020 Jan 03; 21(1):8.
Score: 0.072
-
Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-ß1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018 Jan 30; 19(1):81.
Score: 0.063
-
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial. Intensive Care Med. 2021 Aug; 47(8):867-886.
Score: 0.020